338 related articles for article (PubMed ID: 10220148)
1. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
[TBL] [Abstract][Full Text] [Related]
2. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors.
Marsh DJ; Zheng Z; Arnold A; Andrew SD; Learoyd D; Frilling A; Komminoth P; Neumann HP; Ponder BA; Rollins BJ; Shapiro GI; Robinson BG; Mulligan LM; Eng C
J Clin Endocrinol Metab; 1997 Sep; 82(9):3025-8. PubMed ID: 9284737
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of development of multiple endocrine neoplasia type 2 and Hirschsprung's disease by ret mutations.
Takahashi M; Asai N; Iwashita T; Murakami H; Ito S
Recent Results Cancer Res; 1998; 154():229-36. PubMed ID: 10027003
[TBL] [Abstract][Full Text] [Related]
5. Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells.
Lindahl M; Poteryaev D; Yu L; Arumae U; Timmusk T; Bongarzone I; Aiello A; Pierotti MA; Airaksinen MS; Saarma M
J Biol Chem; 2001 Mar; 276(12):9344-51. PubMed ID: 11116144
[TBL] [Abstract][Full Text] [Related]
6. Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease.
Arighi E; Popsueva A; Degl'Innocenti D; Borrello MG; Carniti C; Perälä NM; Pierotti MA; Sariola H
Mol Endocrinol; 2004 Apr; 18(4):1004-17. PubMed ID: 14715928
[TBL] [Abstract][Full Text] [Related]
7. RET activation by germline MEN2A and MEN2B mutations.
Borrello MG; Smith DP; Pasini B; Bongarzone I; Greco A; Lorenzo MJ; Arighi E; Miranda C; Eng C; Alberti L
Oncogene; 1995 Dec; 11(11):2419-27. PubMed ID: 8570194
[TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of the ret and GDNF genes in a family with multiple endocrine neoplasia type 2A and Hirschsprung disease.
Borrego S; Eng C; Sánchez B; Sáez ME; Navarro E; Antiñolo G
J Clin Endocrinol Metab; 1998 Sep; 83(9):3361-4. PubMed ID: 9745455
[TBL] [Abstract][Full Text] [Related]
9. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
Geneste O; Bidaud C; De Vita G; Hofstra RM; Tartare-Deckert S; Buys CH; Lenoir GM; Santoro M; Billaud M
Hum Mol Genet; 1999 Oct; 8(11):1989-99. PubMed ID: 10484767
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene.
Decker RA; Peacock ML
J Pediatr Surg; 1998 Feb; 33(2):207-14. PubMed ID: 9498388
[TBL] [Abstract][Full Text] [Related]
11. Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas.
Frisk T; Farnebo F; Zedenius J; Grimelius L; Höög A; Wallin G; Larsson C
Eur J Endocrinol; 2000 Jun; 142(6):643-9. PubMed ID: 10822229
[TBL] [Abstract][Full Text] [Related]
12. De novo mutation of GDNF, ligand for the RET/GDNFR-alpha receptor complex, in Hirschsprung disease.
Ivanchuk SM; Myers SM; Eng C; Mulligan LM
Hum Mol Genet; 1996 Dec; 5(12):2023-6. PubMed ID: 8968758
[TBL] [Abstract][Full Text] [Related]
13. Germline mutations of the RET ligand GDNF are not sufficient to cause Hirschsprung disease.
Salomon R; Attié T; Pelet A; Bidaud C; Eng C; Amiel J; Sarnacki S; Goulet O; Ricour C; Nihoul-Fékété C; Munnich A; Lyonnet S
Nat Genet; 1996 Nov; 14(3):345-7. PubMed ID: 8896569
[TBL] [Abstract][Full Text] [Related]
14. Germline mutations in glial cell line-derived neurotrophic factor (GDNF) and RET in a Hirschsprung disease patient.
Angrist M; Bolk S; Halushka M; Lapchak PA; Chakravarti A
Nat Genet; 1996 Nov; 14(3):341-4. PubMed ID: 8896568
[TBL] [Abstract][Full Text] [Related]
15. The sensitivity of activated Cys Ret mutants to glial cell line-derived neurotrophic factor is mandatory to rescue neuroectodermic cells from apoptosis.
Mograbi B; Bocciardi R; Bourget I; Juhel T; Farahi-Far D; Romeo G; Ceccherini I; Rossi B
Mol Cell Biol; 2001 Oct; 21(20):6719-30. PubMed ID: 11564857
[TBL] [Abstract][Full Text] [Related]
16. Mutation of the RET ligand, neurturin, supports multigenic inheritance in Hirschsprung disease.
Doray B; Salomon R; Amiel J; Pelet A; Touraine R; Billaud M; Attié T; Bachy B; Munnich A; Lyonnet S
Hum Mol Genet; 1998 Sep; 7(9):1449-52. PubMed ID: 9700200
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.
De Vita G; Melillo RM; Carlomagno F; Visconti R; Castellone MD; Bellacosa A; Billaud M; Fusco A; Tsichlis PN; Santoro M
Cancer Res; 2000 Jul; 60(14):3727-31. PubMed ID: 10919641
[TBL] [Abstract][Full Text] [Related]
19. [From gene to disease; from the RET gene to multiple endocrine neoplasia types 2A and 2B, sporadic and familial medullary thyroid carcinoma, Hirschsprung disease and papillary thyroid carcinoma].
Hofstra RM; van der Luijt RB; Lips CJ
Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2217-21. PubMed ID: 11757244
[TBL] [Abstract][Full Text] [Related]
20. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
Eng C; Clayton D; Schuffenecker I; Lenoir G; Cote G; Gagel RF; van Amstel HK; Lips CJ; Nishisho I; Takai SI; Marsh DJ; Robinson BG; Frank-Raue K; Raue F; Xue F; Noll WW; Romei C; Pacini F; Fink M; Niederle B; Zedenius J; Nordenskjöld M; Komminoth P; Hendy GN; Mulligan LM
JAMA; 1996 Nov; 276(19):1575-9. PubMed ID: 8918855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
